Matthew T. Wiley
CIK 1759703 · Chief Commercial Officer · last filed 2026-02-05
Matthew T. Wiley is a Chief Commercial Officer who has filed 28 SEC Form 4 insider transactions across 6 companies since 2018. The most recent filing, for DFTX, was dated Feb 5, 2026. Across all open-market trades the lifetime net is +$44.0K, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $2.9M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$2.95M
6
28
$44.0K
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| DFTX | Chief Commercial Officer | 115,000 | $24.75 | $2.85M | $0 | 1 | 2026-02-05 |
| BTAI | Chief Commercial Officer | 25,283 | $1.14 | $28.8K | -$6.6K | 8 | 2025-04-01 |
| Definium Therapeutics, Inc. (MNMD) Delisted | Chief Commercial Officer | — | $15.00 | — | $0 | 1 | 2025-03-18 |
| VYNE | Chief Commercial Officer | 109,246 | $0.65 | $70.8K | $0 | 6 | 2021-07-02 |
| VYNE Therapeutics Inc. (MNLO) Delisted | Chief Commercial Officer | 352,425 | — | — | $0 | 5 | 2020-07-02 |
| Foamix Pharmaceuticals Ltd. (FOMX) Delisted | Chief Commercial Officer | 114,074 | — | — | $50.5K | 6 | 2020-03-03 |
Recent Filings
28 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-02-05 | DFTX | Grant (A) | +115,000 | $0 | EDGAR |
| 2025-04-01 | BTAI | Grant (A) | — | $0 | EDGAR |
| 2025-03-18 | Definium Therapeutics, Inc. (MNMD) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-10-03 | BTAI | Mixed | +14,978 | -$3.4K | EDGAR |
| 2024-09-17 | BTAI | Mixed | +535 | -$149 | EDGAR |
| 2024-09-17 | BTAI | Exer (M) | — | $0 | EDGAR |
| 2024-06-18 | BTAI | Mixed | +506 | -$308 | EDGAR |
| 2024-04-08 | BTAI | Mixed | +1,992 | -$2.7K | EDGAR |
| 2023-03-16 | BTAI | Grant (A) | — | $0 | EDGAR |
| 2022-01-19 | BTAI | Grant (A) | — | $0 | EDGAR |